{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T01:52:04Z","timestamp":1788918724951,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100029642","name":"Skatepark Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100029642","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cancer Policy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jcpo.2025.100660","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T16:41:18Z","timestamp":1762360878000},"page":"100660","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Discrepancies in the therapeutic indications granted by the European Medicines Agency and the US Food and Drug Administration for new cancer drugs: An analysis of potential explanations"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1896-0478","authenticated-orcid":false,"given":"Allan","family":"Cramer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freja Karuna Hemmingsen","family":"S\u00f8rup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne Rolighed","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Karstoft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonny Studsgaard","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcpo.2025.100660_bib1","unstructured":"The European Medicines Agency. Enhancing consistency in wording of therapeutic indications to support healthcare decision-making. 2019. \u3008https:\/\/www.ema.europa.eu\/en\/news\/enhancing-consistency-wording-therapeutic-indications-support-healthcare-decision-making\u3009."},{"key":"10.1016\/j.jcpo.2025.100660_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.7958","article-title":"Use of extrapolation in new drug approvals by the US food and drug administration","volume":"5","author":"Feldman","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jcpo.2025.100660_bib3","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1001\/jamaoncol.2016.5296","article-title":"Overall survival in cancer drug trials as a new surrogate end point for overall survival in the real world","volume":"3","author":"Mailankody","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.jcpo.2025.100660_bib4","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1634\/theoncologist.2018-0307","article-title":"Real-world outcomes of patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors in the year following U.S. regulatory approval","volume":"24","author":"Khozin","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.jcpo.2025.100660_bib5","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1634\/theoncologist.2015-0478","article-title":"Sorafenib effectiveness in advanced hepatocellular carcinoma","volume":"21","author":"Sanoff","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.jcpo.2025.100660_bib6","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.1016\/S1470-2045(23)00357-1","article-title":"Withdrawn accelerated approvals for cancer indications in the USA: what is the marketing authorisation status in the EU?","volume":"24","author":"Cramer","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jcpo.2025.100660_bib7","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1016\/S1470-2045(24)00434-0","article-title":"Differences in the on-label cancer indications of medicinal products between Europe and the USA","volume":"26","author":"Perini","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jcpo.2025.100660_bib8","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1200\/JCO.2010.34.1248","article-title":"Evaluation of oncology drugs at the European Medicines Agency and US Food and Drug Administration: when differences have an impact on clinical practice","volume":"29","author":"Trotta","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jcpo.2025.100660_bib9","unstructured":"Annual reports and work programmes. The European Medicines Agency (EMA). \u3008https:\/\/www.ema.europa.eu\/en\/about-us\/annual-reports-work-programmes\u3009 (accessed May 30, 2024)."},{"key":"10.1016\/j.jcpo.2025.100660_bib10","unstructured":"Novel Drug Approvals at FDA. FDA. \u3008https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/novel-drug-approvals-fda\u3009 (accessed Nov 1, 2023)."},{"key":"10.1016\/j.jcpo.2025.100660_bib11","unstructured":"Advanced therapy medicinal products: Overview. European Medicines Agency (EMA). \u3008https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/advanced-therapy-medicinal-products-overview\u3009 (accessed Oct 13, 2024)."},{"key":"10.1016\/j.jcpo.2025.100660_bib12","unstructured":"Approved Cellular and Gene Therapy Products. U.S. Food & Drug Administration. \u3008https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products\u3009 (accessed Oct 13, 2024)."},{"key":"10.1016\/j.jcpo.2025.100660_bib13","unstructured":"European Medicines Agency. Search the website. \u3008https:\/\/www.ema.europa.eu\/en\/search\/search\u3009 (accessed May 30, 2024)."},{"key":"10.1016\/j.jcpo.2025.100660_bib14","unstructured":"U.S. Food & Drug Administration. Drugs@FDA: FDA-Approved Drugs. \u3008https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm\u3009 (accessed May 30, 2024)."},{"key":"10.1016\/j.jcpo.2025.100660_bib15","doi-asserted-by":"crossref","unstructured":"Lythgoe M., Krell J., Warner J.L., Desai A., Khaki A.R. Time intervals between U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) new cancer therapy approvals. https:\/\/doi.org\/101200\/JCO20213915_suppl1575 2021; 39: 1575\u20131575.","DOI":"10.1200\/JCO.2021.39.15_suppl.1575"},{"key":"10.1016\/j.jcpo.2025.100660_bib16","doi-asserted-by":"crossref","DOI":"10.1111\/bcp.16391","article-title":"Cancer drug applications to the EMA and the FDA: a comparison of new drugs and extension of indication in terms of approval decisions and time in review","author":"Cramer","year":"2025","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jcpo.2025.100660_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2024.5145","article-title":"Regulatory fate of cancer indications in the European Union after accelerated approval in the US","volume":"11","author":"Petersen","year":"2025","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.jcpo.2025.100660_bib18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/cpt.1565","article-title":"A comparison of EMA and FDA decisions for new drug marketing applications 2014\u20132016: concordance, discordance, and why","volume":"107","author":"Kashoki","year":"2020","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.jcpo.2025.100660_bib19","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/s41434-023-00402-4","article-title":"Approval and therapeutic value of gene therapies in the US and Europe","volume":"30","author":"Vokinger","year":"2023","journal-title":"Gene Ther."},{"key":"10.1016\/j.jcpo.2025.100660_bib20","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.9417","article-title":"Treatment patterns and attrition with lines of therapy for advanced urothelial carcinoma in the US","volume":"7","author":"Mathew Thomas","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jcpo.2025.100660_bib21","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.lungcan.2019.02.026","article-title":"Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - results from the prospective German TLK cohort study","volume":"130","author":"Steffens","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jcpo.2025.100660_bib22","article-title":"Therapeutic value of drugs granted accelerated approval or conditional marketing authorization in the US and Europe from 2007 to 2021","volume":"3","author":"Vokinger","year":"2022","journal-title":"JAMA Heal Forum"},{"key":"10.1016\/j.jcpo.2025.100660_bib23","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.47006","article-title":"Cancer drug price and novelty in mechanism of action","volume":"6","author":"Miljkovi\u0107","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jcpo.2025.100660_bib24","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.jval.2023.06.020","article-title":"Cancer drug prices in the United States: efficacy, innovation, clinical trial evidence, and epidemiology","volume":"26","author":"Michaeli","year":"2023","journal-title":"Value Heal"},{"key":"10.1016\/j.jcpo.2025.100660_bib25","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S1470-2045(20)30139-X","article-title":"Prices and clinical benefit of cancer drugs in the USA and Europe: a cost\u2013benefit analysis","volume":"21","author":"Vokinger","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jcpo.2025.100660_bib26","unstructured":"CHMP). Wording of therapeutic indication - A Guide for Assessors of Centralised Application. 2019. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/wording-therapeutic-indication-guide-assessors-centralised-applications_en.pdf\u3009 (accessed Oct 13, 2024)."},{"key":"10.1016\/j.jcpo.2025.100660_bib27","unstructured":"Guideline on the investigation of subgroups in confirmatory clinical trials. The European Medicines Agency. 2019. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-subgroups-confirmatory-clinical-trials_en.pdf\u3009 (accessed Oct 19, 2024)."},{"key":"10.1016\/j.jcpo.2025.100660_bib28","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41573-023-00723-4","article-title":"Trends in the approval of cancer therapies by the FDA in the twenty-first century","volume":"22","author":"Scott","year":"2023","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Journal of Cancer Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538325001043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538325001043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T18:42:47Z","timestamp":1772995367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213538325001043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":28,"alternative-id":["S2213538325001043"],"URL":"https:\/\/doi.org\/10.1016\/j.jcpo.2025.100660","relation":{},"ISSN":["2213-5383"],"issn-type":[{"value":"2213-5383","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discrepancies in the therapeutic indications granted by the European Medicines Agency and the US Food and Drug Administration for new cancer drugs: An analysis of potential explanations","name":"articletitle","label":"Article Title"},{"value":"Journal of Cancer Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcpo.2025.100660","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100660"}}